Medifocus, Inc. to Be Featured on BNN & Fox Business News Network on April 6, 2014: BNN to Air at 9:30 AM & 8:00 PM EDT; Fox Business to Air at 5:30 PM EDT
Submitted by Medifocus Inc. on Friday, 04/04/2014
COLUMBIA, Md. and Toronto, ON- April 4, 2014 – Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, announced today that it will be featured in a 30-minute Life Sciences segment on BNN & Fox Business News Network on Sunday, April 6, 2014. The segment will air at 9:30 AM and 8:00 PM EDT on Canada’s BNN and at 5:30 PM EDT on U.S. Fox Business News.
The segment discusses the Company’s FDA approved, revenue-generating Prolieve® system, a relatively painless and effective alternative to drug therapy and certain types of surgical procedures to treat the symptoms of Benign Prostatic Hyperplasia (BPH). BPH is a non-cancerous urological disease in which the prostate enlarges and constricts the urethra. The Prolieve® system provides a 45-minute in-office treatment that combines microwave thermotherapy capability with a proprietary balloon compression technology to both heat the prostate and dilate the prostatic urethra.
In addition to being aired on April 6th, the excerpt is available on the BTV website at the following link: www.b-tv.com/i/videos/MedifocusApr14.wmv.
Medifocus owns two fully developed technology platforms with comprehensive US and international patent protection: (1) The Endo-thermotherapy Platform — a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The U.S. FDA approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (“BPH”) was developed based on Endo-thermotherapy and is currently generating revenue, and (2) The Adaptive Phased Array (APA) Microwave Focusing Platform — invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company’s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the U.S. FDA and Health Canada to conduct the pivotal Phase III clinical trials. The Company believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.
www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.
This news release contains “forward-looking statements” and “forward-looking information”, which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus’ future growth resulting from the acquisition of additional intellectual property rights, additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking statements are frequently characterized by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company Relations: John Mon, COO, Medifocus, Inc. Tel: 410-290-5734 firstname.lastname@example.org